Article
Oncology
Chi-Shin Tseng, Jui-Han Yang, Shi-Wei Huang, Yu-Jen Wang, Chung-Hsin Chen, Yeong-Shiau Pu, Jason Chia-Hsien Cheng, Chao-Yuan Huang
Summary: This study aimed to investigate the survival outcomes of mCRPC patients receiving first-line ARATs and prognostic factors for patient survival. The results showed that mCRPC patients who had a PSA nadir <= 2 ng/mL or a TTN >= 7 months had better survival.
Article
Oncology
Matti Annala, Sinja Taavitsainen, Daniel J. Khalaf, Gillian Vandekerkhove, Kevin Beja, Joonatan Sipola, Evan W. Warner, Cameron Herberts, Amanda Wong, Simon Fu, Daygen L. Finch, Conrad D. Oja, Joanna Vergidis, Muhammad Zulfiqar, Bernhard J. Eigl, Christian K. Kollmansberger, Matti Nykter, Martin E. Gleave, Kim N. Chi, Alexander W. Wyatt
Summary: In patients with mCRPC, sequential AR signaling inhibitor treatment leads to continuous evolution of the AR genotype, driving acquired resistance mainly through changes in the AR gene.
CLINICAL CANCER RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Jean-Marc Ferrero, Hakim Mahammedi, Gwenaelle Gravis, Guilhem Roubaud, Philippe Beuzeboc, Remi Largillier, Delphine Borchiellini, Claude Linassier, Nathalie Ebran, Tanguy Pace-Loscos, Marie-Christine Etienne-Grimaldi, Renaud Schiappa, Jocelyn Gal, Gerard Milano
Summary: A study on 137 advanced prostate cancer patients treated with the first-line anti-androgen agent AA found that polymorphisms of CYP17A1, SLCO2B1, and SLCO1B3 genes were associated with AA pharmacodynamics. This suggests that host genome characteristics can help predict AA treatment efficacy and identify patients at risk for toxicity.
Article
Oncology
Malou C. P. Kuppen, Hans M. Westgeest, Alphonsus J. M. van den Eertwegh, Reindert J. A. van Moorselaar, Inge M. van Oort, Juleon L. L. M. Coenen, A. C. M. Fons van den Bergh, Niven Mehra, Diederik M. Somford, Andre M. Bergman, Daan Ten Bokkel Huinink, Laurent Fossion, Maud M. Geenen, Mathijs P. Hendriks, Addy C. M. van de Luijtgaarden, Marco B. Polee, Nir Weijl, Agnes J. van de Wouw, Ronald de Wit, Carin A. Uyl-de Groot, Winald R. Gerritsen
Summary: The study examined the treatment outcomes of ART2 in mCRPC patients and found that the effectiveness of ART2 seemed to be low, regardless of the interposition of other LPDs between ART1 and ART2. Results indicated that the PSA response rate and treatment duration of ART2 were relatively short.
EUROPEAN UROLOGY ONCOLOGY
(2021)
Review
Oncology
Emre Yekedüz, Rana R. McKay, Silke Gillessen, Toni K. Choueiri, Yuksel Ürün
Summary: This review evaluates the impact of abiraterone acetate plus prednisone versus non-steroidal anti-androgens on overall survival for metastatic castration-sensitive prostate cancer with visceral metastasis. The analysis shows that abiraterone acetate improves overall survival in patients with visceral metastasis, while second-generation non-steroidal anti-androgens do not provide the same benefit in this population. However, both abiraterone acetate and second-generation non-steroidal anti-androgens improve overall survival in patients without visceral metastasis.
Article
Oncology
Elahe A. Mostaghel, Brett T. Marck, Orpheus Kolokythas, Felix Chew, Evan Y. Yu, Michael T. Schweizer, Heather H. Cheng, Phillip W. Kantoff, Steven P. Balk, Mary-Ellen Taplin, Nima Sharifi, Alvin M. Matsumoto, Peter S. Nelson, R. Bruce Montgomery
Summary: This study found that low levels of circulating adrenal androgens before starting abiraterone acetate were associated with faster progression in metastatic castration-resistant prostate cancer. In addition, low circulating androgens were strongly correlated with an androgen-poor tumor microenvironment and poor response to abiraterone acetate, suggesting potential benefit for patients with higher serum DHEAS levels from dual androgen receptor pathway inhibition.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Jun Li, Nan Liu, Hong Zhou, Peng Xian, Yanping Song, Xianli Tang, Yuan Li, Michael Basler
Summary: This study found that immunoproteasome inhibition has a significant effect on suppressing the progression of castration-resistant prostate cancer (CRPC). The results showed that immunoproteasome inhibition prevents CRPC progression by suppressing inflammation and inducing apoptosis of CRPC cells through activating the unfolded protein response.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Rana R. McKay, Lucia Kwak, Jett P. Crowdis, Jamie M. Sperger, Shuang G. Zhao, Wanling Xie, Lillian Werner, Rosina T. Lis, Zhenwei Zhang, Xiao X. Wei, Joshua M. Lang, Eliezer M. Van Allen, Rupal S. Bhatt, Evan Y. Yu, Peter S. Nelson, Glenn J. Bubley, R. Bruce Montgomery, Mary-Ellen Taplin
Summary: Enzalutamide has shown improved overall survival in metastatic CRPC, but resistance eventually develops. This study found baseline and progression alterations in AR pathway and tumor suppressor genes in a large proportion of patients. Post-enzalutamide, there was an increase in BRCA2 alterations, emphasizing the importance of serial tumor sampling in CRPC.
CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Michele Iuliani, Sonia Simonetti, Giulia Ribelli, Silvia Cavaliere, Bruno Vincenzi, Giuseppe Tonini, Francesco Pantano, Daniele Santini
Summary: Abiraterone, a selective inhibitor of androgen biosynthesis, has been approved for the treatment of prostate cancer. This study provides evidence that abiraterone can inhibit prostate cancer cell proliferation through modulation of multiple osteoblast proliferative signals.
Article
Oncology
Axel S. Merseburger, Gerhardt Attard, Lennart astroem, Vsevolod B. Matveev, Sergio Bracarda, Adil Esen, Susan Feyerabend, Elzbieta Senkus, Marta Lopez-Brea Piqueras, Gunther Boysen, Georgia Gourgioti, Karla Martins, Simon Chowdhury
Summary: The study found that continuing enzalutamide with docetaxel and androgen deprivation therapy can delay progression in men with mCRPC, supporting the idea that enzalutamide maintenance may control persistent androgen-dependent clones.
Article
Medical Laboratory Technology
Maibritt Norgaard, Marianne T. Bjerre, Jacob Fredsoe, Soren Vang, Jorgen B. Jensen, Bram De Laere, Henrik Groenberg, Michael Borre, Johan Lindberg, Karina D. Sorensen
Summary: The clinical utility of low-pass whole-genome sequencing (LPWGS) of circulating tumor DNA (ctDNA) for prognostication in metastatic castration-resistant prostate cancer (mCRPC) was examined. The study found that high ctDNA% and high copy number alteration (CNA) burden at baseline were associated with poor treatment response, progression-free survival (PFS), and overall survival (OS). These findings were confirmed in an independent cohort.
CLINICAL CHEMISTRY
(2023)
Article
Endocrinology & Metabolism
J. Matthijs Moll, Johannes Hofland, Wilma J. Teubel, Corina M. A. de Ridder, Angela E. Taylor, Ralph Graeser, Wiebke Arlt, Guido W. Jenster, Wytske M. van Weerden
Summary: In CRPC, adrenal androgen precursors promote cell growth while de novo synthesized precursor steroids do not. Abiraterone inhibits growth induced by adrenal cells and the presence of adrenal tumors promotes CRPC growth.
Article
Urology & Nephrology
Benjamin Lowentritt, Gordon Brown, Dominic Pilon, Lorie Ellis, Guillaume Germain, Carmine Rossi, Patrick Lefebvre, Kenneth Kernen, Paul Sieber, Neal Shore
Summary: This study aims to describe the PSA response and treatment adherence of patients with non-metastatic castration-resistant prostate cancer treated with apalutamide, overall and stratified by race.
Article
Oncology
Sha Zhu, Yuchao Ni, Guangxi Sun, Zilin Wang, Junru Chen, Xingming Zhang, Jinge Zhao, Xudong Zhu, Jindong Dai, Zhenhua Liu, Jiayu Liang, Haoran Zhang, Yaowen Zhang, Pengfei Shen, Hao Zeng
Summary: The expression level of exosomal TUBB3 mRNA is associated with poor PSA-PFS in mCRPC patients treated with abiraterone, with TUBB3 (+) and ECOG score >2 being independent predictors of unfavorable PSA-PFS.
Article
Oncology
Takashi Kawahara, Yusuke Saigusa, Shuko Yoneyama, Masashi Kato, Ippei Kojima, Hiroshi Yamada, Osamu Kamihira, Kenichi Tabata, Hideyasu Tsumura, Masatsugu Iwamura, Kazuhide Makiyama, Hiroji Uemura, Yasuhide Miyoshi
Summary: A prognostic nomogram and calculator were developed to predict the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone acetate (ABI) and/or enzalutamide (ENZ). Time to CRPC, pre-chemotherapy, baseline prostate-specific antigen, baseline alkaline phosphatase, and baseline lactate dehydrogenase levels were identified as independent risk factors for overall survival (OS). The developed nomogram and calculator showed good accuracy in predicting patient prognosis.
Article
Endocrinology & Metabolism
Elena Flowers, Bradley E. Aouizerat, Alka M. Kanaya, Jose C. Florez, Xingyue Gong, Li Zhang
Summary: This study identified 5 miRs (miR-144, miR-186, miR-203a, miR-205, miR-206) that can effectively predict the incidence of type 2 diabetes. After adjusting for covariates, the HR for the highest quartile risk group compared with the lowest quartile risk group was 5.91. There was significant interaction between the intensive lifestyle and metformin groups compared with placebo. These findings may have potential clinical utility for risk stratification of individuals with prediabetes.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Oncology
Crystal S. Langlais, Yea -Hung Chen, Erin L. Van Blarigan, June M. Chan, Charles J. Ryan, Li Zhang, Hala T. Borno, Robert U. Newton, Anthony Luke, Alexander S. Bang, Neil Panchal, Imelda Tenggara, Brooke Schultz, Emil Lavaki, Nicole Pinto, Rahul Aggarwal, Terence Friedlander, Vadim S. Koshkin, Andrea L. Harzstark, Eric J. Small, Stacey A. Kenfield
Summary: This study aimed to evaluate the effects of a 12-week remotely monitored exercise program on quality of life (QoL) in men with metastatic castrate-resistant prostate cancer (mCRPC). The results showed that compared to the control group, the resistance exercise group reported improvements in social function and urinary irritative/obstruction symptoms, while the aerobic exercise group reported improvements in social function and urinary incontinence, but worsening nausea/vomiting. The study suggests that exercise intervention has a modest effect on QoL in mCRPC patients and further research is warranted.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Oncology
Nitya Raj, Jennifer A. Chan, Stephanie J. Wang, Rahul R. Aggarwal, Susan Calabrese, April DeMore, Lawrence Fong, Jennifer Grabowsky, Thomas A. Hope, Kanti Pallav Kolli, Claire K. Mulvey, Pamela N. Munster, Kimberly Perez, Sippy Punn, Diane Reidy-Lagunes, Sofia Von Fedak, Li Zhang, Emily K. Bergsland
Summary: Single-agent immune checkpoint inhibitor therapy has shown limited effectiveness against EP-PDNECs, and the efficacy of combination therapy with chemotherapy is still being investigated. This study evaluated the effectiveness of pembrolizumab alone and pembrolizumab plus chemotherapy in patients with advanced EP-PDNECs.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Arian Lundberg, Meng Zhang, Rahul Aggarwal, Haolong Li, Li Zhang, Adam Foye, Martin Sjostrom, Jonathan Chou, Kevin Chang, Thaidy Moreno-Rodriguez, Raunak Shrestha, Avi Baskin, Xiaolin Zhu, Alana S. Weinstein, Noah Younger, Joshi J. Alumkal, Tomasz M. Beer, Kim N. Chi, Christopher P. Evans, Martin Gleave, Primo N. Lara, Rob E. Reiter, Matthew B. Retting, Owen N. Witte, Alexander W. Wyatt, Felix Y. Feng, Eric J. Small, David A. Quigley
Summary: This study comprehensively characterized treatment-emergent mCRPC by integrating different sequencing techniques and found that AR-/NE- tumors were clinically and molecularly distinct with the shortest survival. In addition, the study identified CHD7 amplification and PTEN loss in these tumors, and linked elevated CHD7 expression to methylation changes in candidate enhancers. The study also revealed KLF5 as a driver of the AR-/NE- phenotype and its activity was linked to RB1 loss.
Article
Oncology
Anil P. Bidkar, Sinan Wang, Kondapa Naidu Bobba, Emily Chan, Scott Bidlingmaier, Emily A. Egusa, Robin Peter, Umama Ali, Niranjan Meher, Anju Wadhwa, Suchi Dhrona, Chandrashekhar Dasari, Denis Beckford-Vera, Yang Su, Ryan Tang, Li Zhang, Jiang He, David M. Wilson, Rahul Aggarwal, Henry F. VanBrocklin, Youngho Seo, Jonathan Chou, Bin Liu, Robert R. Flavell
Summary: This study developed the radioimmunotherapy agent [225Ac]DOTA-YS5 based on the YS5 antibody and evaluated its therapeutic efficacy and toxicity. The results showed that [225Ac]DOTA-YS5 effectively suppressed the growth of cell-derived and patient-derived xenografts, including both prostate-specific membrane antigen-positive and prostate-specific membrane antigen-deficient models. These findings suggest that CD46-targeted radioligand therapy with [225Ac]DOTA-YS5 has high clinical translational potential in prostate cancer.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Bryan Khuong Le, Patrick McGarrah, Alan Paciorek, Amr Mohamed, Andrea B. Apolo, David L. Chan, Diane Reidy-Lagunes, Haley Hauser, Jaydira D. Rivero, Julia Whitman, Kathleen Batty, Li Zhang, Nitya Raj, Tiffany Le, Emily Bergsland, Thorvardur R. Halfdanarson
Summary: This study reviewed the treatment patterns and oncologic outcomes of patients with U-NENs in the recent era of NEN therapy. It found that PDNECs were more common in bladder NENs, while WDNETs predominated in non-bladder tumors. Potential disease control activity was observed in WD-UNETs treated with PRRT and everolimus.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Tanya Jindal, Li Zhang, Prianka Deshmukh, Kevin Reyes, Emily Chan, Vipul Kumar, Xiaolin Zhu, Edward Maldonado, Stephanie Feng, Michelle Johnson, Austin Angelidakis, Daniel Kwon, Arpita Desai, Hala T. Borno, Rohit Bose, Anthony Wong, Julian Hong, Peter Carroll, Maxwell Meng, Sima Porten, Rahul Aggarwal, Eric J. Small, Lawrence Fong, Jonathan Chou, Terence Friedlander, Ivan de Kouchkovsky, Vadim S. Koshkin
Summary: Urothelial carcinoma with squamous differentiation (UCS) is a common variant of bladder cancer, and the treatment outcomes with novel agents for UCS patients are largely unknown. In this retrospective analysis, UCS patients treated with immune checkpoint inhibitors or Enfortumab vedotin had inferior outcomes compared to patients with pure UC.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Brian M. Haas, Li Zhang, Heather Nichols, Nathan Orwig, Christopher P. Hess, K. Pallav Kolli
Summary: The study aimed to identify the aspects of the referring clinician experience that have the strongest correlation with overall satisfaction, which are of greatest relevant importance to referring clinicians. A survey was conducted among 2720 clinicians, assessing their satisfaction in 11 domains of the radiology process map. The findings revealed that nearly every question was associated with overall satisfaction, and the factors most strongly correlated with overall satisfaction were results/reporting overall, section with which work most closely overall, and inpatient radiology overall.
Article
Oncology
Lufan Wang, Crystal Langlais, Stacey A. Kenfield, Katherine Van Loon, Angela Laffan, Chloe E. Atreya, June M. Chan, Li Zhang, Isabel E. Allen, Christine Miaskowski, Yoshimi Fukuoka, Jeffrey A. Meyerhardt, Alan P. Venook, Erin L. Van Blarigan
Summary: This study aimed to assess the effect of a 12-week web-based dietary intervention with text messages on quality of life among colorectal cancer survivors. The results showed that participants receiving the intervention experienced improvements in emotional functioning and social functioning at 12 and 24 weeks. There was also a decrease in fatigue at 24 weeks. However, no other changes in quality of life scores were associated with the intervention.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Vivian N. N. Liu, Kyle B. B. Zuniga, Alan Paciorek, Li Zhang, June M. M. Chan, Peter R. R. Carroll, Katherine Van Loon, Angela Laffan, Alan Venook, Erin L. L. Van Blarigan, Stacey A. A. Kenfield
Summary: Remote-based behavioral interventions can help cancer survivors overcome barriers to healthy diet and exercise, such as lack of discipline, time, energy, and knowledge. Both colorectal cancer and prostate cancer survivors commonly face barriers related to motivation, time, social support, and lack of knowledge.
SUPPORTIVE CARE IN CANCER
(2023)
Letter
Surgery
Tasce Bongiovanni, Elizabeth Lancaster, Matthias Behrends, Li Zhang, Elizabeth Wick, Andrew Auerbach, Mark J. Pletcher
Article
Immunology
Hai Yang, Jason Cham, Brian Patrick Neal, Zenghua Fan, Tao He, Li Zhang
Summary: T cells are important for adaptive immunity and play a role in anti-tumoral immunity and defense against infections, including respiratory viruses like SARS-CoV-2. A customized pipeline for Network Analysis of Immune Repertoire (NAIR) was developed to analyze T-cell receptor (TCR) sequences. Network analysis and statistical methods were used to characterize the repertoire and correlate it with clinical outcomes. Disease-specific/associated clusters and shared clusters were identified, and a new metric incorporating clonal generation probability and clonal abundance was used to identify disease-specific TCRs. The proposed approach revealed potential disease-specific TCRs responsible for the immune response to COVID-19.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Andrew D. Chapp, Andrea R. Collins, Kyle M. Driscoll, Jessica E. Behnke, Zhiying Shan, Li Zhang, Qing-Hui Chen
Summary: Acetate exerts an excitatory effect on amygdala neurons and cytosolic calcium signaling, potentially through activation of NMDA receptors. These findings provide insights into the underlying mechanisms of ethanol consumption on autonomic circuitry.
ACS CHEMICAL NEUROSCIENCE
(2023)
Meeting Abstract
Oncology
Samuel L. Washington, Julie A. Szymaniak, Pedro Gallardo, Chengshi Jin, Li Zhang, Sima Porten, Maxwell V. Meng, Matthew R. Cooperberg, Peter R. Carroll
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2023)
Meeting Abstract
Oncology
Maira Soto, Erin L. Filbert, Hai Yang, Li Zhang, Stephanie Starzinski, Alec Starzinski, Alexander Cheung, Tony Li, Frank J. Hsu, Andrew H. Ko, Lawrence Fong, Bridget P. Keenan
JOURNAL OF CLINICAL ONCOLOGY
(2023)